|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Dror Ben-Asher||Co-Founder, Chairman & CEO||448,42k||N/D||1966|
|Mr. Micha Ben-Chorin||Chief Financial Officer||339,01k||N/D||1969|
|Mr. Gilead Raday||Chief Operating Officer||361,68k||N/D||1975|
|Mr. Adi Frish||Sr. VP of Bus. Devel. & Licensing||338,12k||N/D||1970|
|Mr. Guy Goldberg||Chief Bus. Officer||338,13k||N/D||1976|
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of drugs for gastrointestinal diseases. The company promotes various gastrointestinal drugs, including Movantik for opioid-induced constipation in adults; Talicia for the treatment of Helicobacter pylori bacterial infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its late-stage clinical development programs include RHB-104, which is in Phase 3 study for treating Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) that is in first Phase 3 study to treat acute gastroenteritis and gastritis, as well as has completed Phase 2 study for treating irritable bowel syndrome with diarrhea; RHB-106, which is in planned Phase 2/3 studies for bowel preparation; ABC294640 (Yeliva), a SK2 selective inhibitor, which is in Phase 1/2a study for treating cholangiocarcinoma, as well as in Phase 2 study for prostate cancer; and RHB-107 that is in planned pilot study for cholangiocarcinoma, as well as has completed Phase 2 study for gastrointestinal and other solid tumors. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
L'ISS Governance QualityScore di RedHill Biopharma Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.